Subgroup analysis showed the potential for substantial reduction in the risk of GC-related death and relapse after S-1 adjuvant chemotherapy in patients who were TLC-IκBα double negative (Fig. 6, C and E). This evidence concerns the gene NFKBIA and gastric cancer.